Diethylamine

Diethylamine

SCHEMBL571942

CCCCCCc1ccccc1C(=O)OC(=O)c1ccccc1O.CCNCC

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CCKAR

The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 3/20 0.48
MCL1 Q07820 3/20 0.48
BCL2L1 Q07817 2/20 0.48
BAK1 Q16611 2/20 0.48
KAT8 Q9H7Z6 2/20 0.48
SAE1 Q9UBE0 2/20 0.48
NAAA Q02083 1/20 0.48
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
EP300 Q09472 1/20 0.48
KAT2A Q92830 1/20 0.48
KAT2B Q92831 1/20 0.48
KAT5 Q92993 1/20 0.48
LMNA P02545 3/20 0.44
TSHR P16473 2/20 0.44
MMP2 P08253 2/20 0.43
F7 P08709 2/20 0.43
F3 P13726 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570967 0.94 BID (0.54) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL30656414 0.85 TSHR (0.53) BIDMCL1BCL2L1BAK1KAT8
Emylcamate SCHEMBL29074632 0.81 BID (0.42) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL8512469 0.81 TSHR (0.51) LMNATSHRHSD17B10ALDH1A1THRA
SCHEMBL1790208 0.80 TSHR (0.48) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL9578113 0.80 TSHR (0.50) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL3290584 0.80 BID (0.48) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL29054012 0.80 PLK1 (0.43) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL29148965 0.80 ALDH1A1 (0.62) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL11552750 0.80 ALDH1A1 (0.62) BIDMCL1BCL2L1BAK1KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3600224-B1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2026-05-06 EP claimed
CN-119970593-A Sun-screening composition, application thereof and skin care product 东烽化学(杭州)有限公司广州分公司 2025-05-13 CN claimed
CN-119523833-A Collagen microsphere ergothioneine compound, multifunctional high-efficiency broad-spectrum sun-screening composition containing compound and preparation method 南京天纵易康生物科技股份有限公司 2025-02-28 CN claimed
US-12214067-B2 Oil-in-water emulsion sunscreen composition ISP INVESTMENTS INC. (US) 2025-02-04 US claimed
US-20220387290-A1 SUNSCREEN COMPOSITIONS AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2022-12-08 US claimed
WO-2022214187-A1 AN O/W EMULSION BASE AND EMULSIONS COMPRISING THE SAME SYMRISE AG (DE) 2022-10-13 WO claimed
US-20220125701-A1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2022-04-28 US claimed
EP-3946642-A1 SUNSCREEN COMPOSITIONS AND METHOD OF USE THEREOF ISP Investments LLC (US) 2022-02-09 EP claimed
US-20210338539-A1 LAMELLAR GEL BASED PERSONAL CARE COMPOSITIONS, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC 2021-11-04 US claimed
EP-2701670-B1 CLEAR WET SUN-CARE SPRAYS AND GELS ISP INVESTMENTS LLC (US) 2021-10-20 EP claimed
EP-3099284-A1 OIL-IN-WATER EMULSION SUNSCREEN COMPOSITION ISP Investments Inc. (US) 2016-12-07 EP claimed
EP-2257266-B1 COMPOSITIONS DESIGNED TO PREVENT/PROTECT AGAINST PHOTOALLERGIC AND PHOTOTOXIC SKIN REACTIONS BRAGUTI LODOVICO GIANLUCA (IT) 2016-03-16 EP claimed
WO-2015116899-A1 OIL-IN -WATER EMULSION SUNSCREEN COMPOSITION ISP INVESTMENTS INC. (US) 2015-08-06 WO claimed
US-8673272-B2 Ultraviolet-absorbing compounds ISP INVESTMENTS INC. (US) 2014-03-18 US claimed
EP-2701670-A1 CLEAR WET SPRAYS AND GELS Isp Investments Inc. (US) 2014-03-05 EP claimed
US-20140030198-A1 CLEAR WET SPRAYS AND GELS ISP INVESTMENT INC. (US) 2014-01-30 US claimed
WO-2012149355-A1 CLEAR WET SPRAYS AND GELS ISP INVESTMENTS INC. (US) 2012-11-01 WO claimed
US-20110020251-A1 Ultraviolet-Absorbing Compounds AVOCA LLC 2011-01-27 US claimed
EP-2257266-A2 COMPOSITIONS DESIGNED TO PREVENT/PROTECT AGAINST PHOTOALLERGIC AND PHOTOTOXIC SKIN REACTIONS Braguti, Lodovico Gianluca (IT) 2010-12-08 EP claimed
WO-2009129904-A2 COMPOSITIONS DESIGNED TO PREVENT/PROTECT AGAINST PHOTOALLERGIC AND PHOTOTOXIC SKIN REACTIONS BRAGUTI LODOVICO GIANLUCA (IT) 2009-10-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020251-A1 Ultraviolet-Absorbing Compounds UFM1, UHRF1, CUTA BID 2038/4885MCL1 3537/4885BCL2L1 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.